Chief, Reasearch and Immuno-Oncology
Oncology
Dr. Omid Hamid, MD
|
|
Give Review
Omid Hamid works in the field of Oncology. He attended Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31/72 in Research/PrimaryCare. Omid Hamid is a published MD. He has 23 publications published. The most current publication "Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab." Omid Hamid accepts all Medicare patients.
Publications
- Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic Melanoma.
- Randomized Phase 2 Study Evaluating Veliparib (ABT-888) With Temozolomide in Patients With Metastatic Melanoma.
- Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV Melanoma.
- Characteristics of pyrexia in BRAFV600E/K metastatic Melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial.
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type.
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in Cancer patients.
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma.
- Survival follow-up and ipilimumab retreatment for patients with advanced Melanoma who received ipilimumab in prior phase II studies.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced Melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
- Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer.
- A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic Melanoma.
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma.
- Safety and tumor responses with lambrolizumab (anti-PD-1) in Melanoma.
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in Cancer therapy.
- Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy in a Patient with Metastatic Melanoma.
- Ipilimumab for metastatic Melanoma.
- Selecting Patients for KIT Inhibition in Melanoma.
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
- Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Schools
Keck Sch Of Med Of The Usc
University Of S CaLac and Usc
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Education
-
University of Southern California - LAC+USC Medical Center -
Keck School of Medicine of USC
Hospital
-
Ronald Reagan UCLA Medical Center -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1215966775 | |
| NPPES Provider LastName | HAMID | |
| NPPES Provider FirstName | OMID | |
| NPPES Provider ZIPCode | 904042102 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 468.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 27.0 | |
| Percent Opioid Claims | 5.77 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215966775 |
| Last Name Of The Provider | HAMID |
| First Name Of The Provider | OMID |
| View All |
Similar Doctors
|
Dr. Sant P. Chawla, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Marilou Terpenning, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara A. Hurvitz, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andrew E. Hendifar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan Bukata, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel R. Hecht, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Saeed W. Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamalesh K. Sankhala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francis P. Cyran, MD
This Doctor is OpenDoctor Recommended.
|